Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination

News   Jun 09, 2008

 
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination
 
 
 

RELATED ARTICLES

RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis B

News

The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.

READ MORE

A More Effective Alternative to RNAi, CRISPR for Studying Protein Function

News

Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.

READ MORE

New Blood Test Developed to Diagnose Ovarian Cancer

News

Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE